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1  | INTRODUC TION
Unlike	several	other	neurodegenerative	diseases,	Huntington's	dis‐
ease	(HD)	has	clear	genetic	background	where	huntingtin	gene	(HTT)	
has	an	abnormally	expanded	CAG	repeat	near	the	N	terminus.	This	
causes	production	of	mutant	huntingtin	(mHtt)	protein	with	polyglu‐
tamine‐expanded	(polyQ)	tail,	and	over	36	CAG	repeats	cause	aggre‐
gation‐prone	polyQ	tail.	This	 leads	to	accumulation	of	 intracellular	
aggregates	of	mHtt	 in	 the	 cell	 producing	 toxicity	with	deleterious	
effects	on	gene	transcription,	protein	processing	and	cell	signalling	
cascades	ultimately	leading	to	neuronal	death	(for	review,	see	Ref.1).	
Clinically,	HD	is	characterized	by	severe	symptoms	such	as	impaired	
movement	and	chorea	as	well	as	declined	cognitive,	and	there	are	
currently	no	rational	treatments.	Recently,	great	interests	have	been	
devoted	 to	 the	possibility	 to	 reduce	mHtt	burden	by	 lowering	 the	
expression	 levels	of	mHtt	using	DNA‐	or	RNA‐targeted	 therapies.	
However,	these	approaches	are	in	their	infancy	and	may	bear	risks	
related	to	complete	loss	of	Htt	that	may	have	toxic	effects.2
An	alternative	way	to	interfere	with	the	aggregates	would	be	to	
increase	the	degradation	rate	of	mHtt.	As	a	background	to	this	 is	
the	finding	that	mHtt	aggregates	are	known	to	impair	the	ubiquitin‐
proteasome	 system	causing	 a	 further	 increase	 in	 the	 intracellular	
protein	 load	 in	cells.	 In	addition,	autophagy	 inducers	can	produce	
beneficial	effects	 in	cell	culture	and	animal	models	of	HD	(for	re‐
view,	see	Ref.3).	However,	the	potential	toxicity	and	adverse	effects	
of	such	autophagy	inducers	may	also	cause	serious	drawbacks	that	
has	to	be	taken	into	account.4
Prolyl	oligopeptidase	(PREP)	is	mainly	cytosolic	enzyme	involved	
in	peptide	bond	cleavage	that	was	recently	shown	to	negatively	reg‐
ulate	 autophagy.5	KYP‐2047	 is	 a	 small‐molecule	 inhibitor	 of	PREP	
having	a	disease‐modifying	effect	in	the	alpha‐synuclein	(aSyn)	mod‐
els	of	Parkinson´s	disease	(for	review,	see	Ref.6).	We	have	shown	that	
KYP‐2047	 reduced	 the	 amount	of	 aSyn‐aggregates	 in	 in	 vitro	 and	
in	vivo	by	activating	autophagy,	while	PREP	directly	interacts	with	
aSyn	and	colocalizes	with	aSyn	in	Parkinsonian	brain.6,7	Interestingly,	
we	observed	that	PREP	is	also	expressed	in	the	striatum	and	partic‐
ularly	in	the	medium	spiny	neurons8	that	preferentially	degenerate	
in	HD.1	This	prompted	us	to	study	whether	the	 inhibition	of	PREP	
could	interfere	with	mHtt	and	reduce	its	aggregation	in	cell	models	
of	HD.
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2  | MATERIAL S AND METHODS
2.1 | Reagents
Reagents	were	purchased	from	Sigma‐Aldrich	if	not	otherwise	speci‐
fied.	See	Materials	S1	for	details.
2.2 | Cell cultures
mHtt	stably	expressing	HeLa	cells	having	the	first	17	amino	acids	
of	Htt	 linked	 to	 a	 103Q	 polyQ	 repeat	 tagged	 to	 green	 fluores‐
cent	protein	(GFP)9	were	used	in	the	study.	See	Materials	S1	for	
details.
2.3 | Cell viability assay
Cell	 viability	 was	 studied	 with	 basic	 cell	 viability	 assays.10 See 
Materials	S1	for	details.
2.4 | Western blot
Immunoblotting	was	performed	by	using	 standard	SDS‐PAGE	and	
transfer	methods	as	previously	described.5	More	detailed	protocol	
and	antibody	details	are	presented	in	Materials	S1.
2.5 | Immunocytochemistry (ICC)
ICC	was	used	to	detect	Htt	aggregation	after	proteasomal	inhibition	
as	described	earlier.11	Detailed	protocol	is	presented	in	Materials	S1.
2.6 | Statistical analysis
Statistical	 analyses	 were	 performed	 using	 GraphPad	 Prism	 (ver‐
sion	6.02,	GraphPad	Software),	and	the	one‐way	ANOVA	test	with	
Tukey's	post	hoc	comparison	and	multiple	Student's	t	test.	Data	are	
presented	as	mean	±	SEM,	and	differences	were	considered	statisti‐
cally	significant	at	P < .05.
F I G U R E  1  KYP‐2047	attenuates	
lactacystin‐induced	toxicity	in	103Q‐
expressing	HeLa	cells.	Wild‐type	(A‐B)‐,	
25Q	(C‐D)‐	and	103Q	(E‐F)‐expressing	
HeLa	cells	were	exposed	to	increasing	
amounts	of	a	proteasomal	inhibitor,	
lactacystin	(1	nmol/L	to	100	µmol/L).	
About	100	µmol/L	of	lactacystin	
was	particularly	toxic	for	103Q	HeLa	
cells	(E)	in	LDH	assay	and	1	µmol/L	
KYP‐2047	significantly	decreased	LDH	
release.	About	100	µmol/L	lactacystin	
was	toxic	for	all	cell	lines	but	in	103Q	
HeLa,	1	µmol/L	KYP‐2047	attenuated	
lactacystin	toxicity	(F).*P	<	.05,	Student's	
t	test	(n	of	parallel	samples	=	3;	n	of	
individual	experiments	=	3)
     |  3NORRBACKA et Al.
F I G U R E  2  PREP	inhibition	reduces	103Q	aggregation	in	cells.	103Q	cells	showed	clear	aggregates	instead	of	diffuse	soluble	staining	
after	lactacystin	exposure	(A‐B),	and	simultaneous	incubation	with	1	µmol/L	KYP‐2047	reduces	cytosolic	aggregates	(C).	Further	analysis	
by	Western	blot	showed	significant	decrease	in	insoluble	GFP	levels	(HMW	GFP)	in	103Q	cells	while	in	25Q	cells	showed	no	significant	
aggregation	(D‐E).	Beclin1	levels	were	not	significantly	increased	by	KYP‐2047	(F‐G)	but	LC3BII	was	significantly	elevated	in	103Q	cells	
compared	to	control	(I).	*P	<	.05;	**P	<	.01;	***P	<	.001,	1‐way	ANOVA	with	Tukey	post‐test	(n	of	parallel	samples	=	2;	n	of	individual	
experiments	=	3)
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3  | RESULTS AND DISCUSSION
3.1 | PREP inhibition attenuates mHtt 103Q toxicity 
after proteasomal inhibition
Wild‐type	 HeLa	 cells,	 and	 HeLa	 cells	 expressing	 either	 25Q‐	 or	
103Q‐containing	Htt	protein	were	cultured	for	48	hours	in	the	pres‐
ence	of	1	nmol/L	to	100	µmol/L	of	lactacystin.	This	is	to	model	defi‐
cits	in	the	protein	processing	that	is	common	characteristic	of	HD.12 
Increasing	 the	 concentration	 of	 lactacystin	 reduced	 cell	 viability	
specifically	of	103Q‐expressing	cells	using	the	LDH	assay	and	this	
could	be	reversed	using	1	µmol/L	KYP‐2047	(Figure	1A,C,E;	P	<	.05,	
multiple	Student's	 t	 test).	 Interestingly,	100	µmol/L	 lactacystin	 re‐
duced	 the	MTT	signal	 in	wild‐type‐	and	25Q‐expressing	cells,	and	
KYP‐2047	did	not	attenuate	this	(Figure	1B,D).	In	103Q	cells,	PREP	
inhibition	significantly	improved	cell	viability	also	in	the	MTT	assay	
(Figure	1F;	P	<	.05,	multiple	Student's	t	test).
Data	 show	 that	 high‐dose	 of	 lactacystin	 is	 toxic	 for	 cells	 even	
without	 polyQ	 overexpression.	 However,	 significant	 and	 dose‐de‐
pendent	 toxicity	 in	 LDH	 assay	 was	 seen	 only	 in	 103Q‐expressing	
cells,	 indicating	that	 longer	polyQ	tract	 increases	toxicity	similar	 to	
human	HD.1	LDH	measures	cell	membrane	damages,	and	plasma	and	
organelle	membrane	damage	are	associated	with	mHtt	aggregation	
in	HD.1	Therefore,	it	seemed	worthwhile	to	study	whether	addition	
of	KYP‐2047	would	affect	the	aggregation	of	mHtt	protein	in	these	
cells.
3.2 | PREP inhibition reduces mHtt 103Q 
aggregates in cells
103Q	 cells	 were	 immunostained	 to	 detect	 polyQ	 aggregates	 in	
control	 and	 lactacystin‐treated	 cells.	 ICC	 showed	 that	 untreated	
103Q‐expressing	cells	had	a	diffuse	staining	of	mHtt,	while	addition	
of	10	µmol/L	lactacystin	for	48	hours	induced	the	formation	of	GFP‐
positive	 aggregates	 that	 were	 visible	 also	 in	 nuclei	 (Figure	 2A‐B).	
Simultaneous	incubation	of	cells	with	1	µmol/L	KYP‐2047	reduced	
the	cytosolic	aggregates	(Figure	2C)	but	did	not	have	an	impact	on	
the	nuclear	aggregates.
Next,	 we	 performed	 immunoblots	 on	 cell	 fractions	 obtained	
from	25Q‐	and	103Q‐expressing	cells.	For	this,	cells	were	fractioned	
into	 soluble	 and	 SDS‐soluble/insoluble	 fractions	 as	 described	 in	
Methods.	There	was	a	significant	increase	in	high‐molecular‐weight	
(HMW)	 mHtt	 particles,	 representing	 insoluble	 aggregates,	 in	 the	
103Q	expression	 but	 not	 in	 the	 25Q‐expressing	 cells	 (Figure	 2D).	
In	contrast,	the	amount	of	soluble	mHtt	levels	remained	largely	un‐
changed	(Figure	S1).
We	 have	 earlier	 shown	 that	 inhibition	 of	 PREP	 can	 increase	
Beclin1‐mediated	autophagy.5	Therefore,	we	measured	the	levels	
of	Beclin1	and	LC3BII	in	the	soluble	fractions	of	25Q‐	and	103Q‐
expressing	cells.	Data	showed	that	the	conversion	of	LC3	into	ac‐
tive	LC3BII	in	autophagy	was	significantly	increased	by	KYP‐2047	
in	lactacystin‐treated	103Q	cells	(Figure	2I).	However,	Beclin1	was	
not	 significantly	 changed	 although	 KYP‐2047	 increased	 it	 after	
lactacystin	 incubation	 (Figure	 2G).	 Longer	 polyQ	 tracts	 are	 re‐
ported	to	 increase	the	degradation	of	Beclin113	but	 this	was	not	
seen	in	our	study.	However,	if	KYP‐2047	can	increase	the	levels	of	
Beclin1	(as	shown	in	Ref.5),	this	could	be	beneficial	in	HD.	In	25Q	
cells,	there	were	no	significant	alterations	in	LC3BII	or	in	Beclin1	
levels.	Additionally,	we	studied	 the	 levels	of	p62	 in	 soluble	 frac‐
tion	but	no	changes	were	observed	(Figure	S1).	Together,	this	sug‐
gests	that	lactacystin	induced	mainly	the	aggregation	of	insoluble	
mHtt	 in	 103Q‐expressing	 cells	 and	 this	was	 counteracted	 using	
KYP‐2047.
In	conclusion,	our	data	show	that	PREP	inhibition	is	able	to	at‐
tenuate	the	toxicity	of	103Q‐mHtt	protein	by	enhancing	the	auto‐
phagy‐mediated	clearance	of	insoluble	cytosolic	polyQ	aggregates	
as	we	have	shown	with	aggregated	aSyn.6	It	should	be	remembered	
that	 pharmacological	 activation	 of	 autophagy	 may	 under	 certain	
conditions	cause	apoptosis	rendering	them	less	attractive	for	clin‐
ical	use.4	However,	 the	concept	of	PREP	 inhibition	has	been	con‐
sidered	safe	also	 in	clinical	 trials14	 and	we	propose	 that	 targeting	
PREP	and	its	inhibition	can	be	considered	as	an	attractive	possibility	
for	lowering	the	burden	of	mHtt	and	cell	toxicity	in	HD.	However,	
further	 studies	with	PREP	 inhibitors	on	animal	models	of	HD	are	
needed.
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